A5011060620- CAR-T cell therapy research
- 3D Printing in Biomedical Research
- Immunotherapy and Immune Responses
- Proteoglycans and glycosaminoglycans research
- Cell Image Analysis Techniques
- Nanowire Synthesis and Applications
- Advancements in Semiconductor Devices and Circuit Design
- T-cell and B-cell Immunology
- Mesenchymal stem cell research
- Viral Infectious Diseases and Gene Expression in Insects
- Nerve injury and regeneration
- Cellular Mechanics and Interactions
- Nanofabrication and Lithography Techniques
- Extracellular vesicles in disease
- Virus-based gene therapy research
- Neuroblastoma Research and Treatments
- Osteoarthritis Treatment and Mechanisms
- Dendrimers and Hyperbranched Polymers
- Tissue Engineering and Regenerative Medicine
- Cell Adhesion Molecules Research
- Intestinal and Peritoneal Adhesions
- Microfluidic and Bio-sensing Technologies
- Glycosylation and Glycoproteins Research
- Characterization and Applications of Magnetic Nanoparticles
- Psychedelics and Drug Studies
California University of Pennsylvania
2023-2025
University of Pennsylvania
2022-2024
Philadelphia University
2022-2023
University of Georgia
2016-2023
Emory University
2017
A major limitation of chimeric antigen receptor (CAR) T cell therapies is the poor persistence these cells in vivo
Bispecific T cell engagers (BiTEs) are bispecific antibodies that redirect cells to target antigen-expressing tumors. We hypothesized BiTE-secreting could be a valuable therapy in solid tumors, with distinct properties mono- or multi-valent strategies incorporating chimeric antigen receptor (CAR) cells. Glioblastomas represent good model for tumor heterogeneity, representing significant therapeutic challenge. detected expression of tumor-associated epidermal growth factor (EGFR), EGFR...
Abstract Bone morphogenetic protein 2 (BMP-2)-loaded collagen sponges remain the clinical standard for treatment of large bone defects when there is insufficient autograft, despite associated complications. Recent efforts to negate comorbidities have included biomaterials and gene therapy approaches extend duration BMP-2 release activity. In this study, we compared sponge chondroitin sulfate glycosaminoglycan (CS-GAG) scaffolds as a delivery vehicle recombinant human (rhBMP-2) rhBMP-2...
Stroke causes significant mortality and morbidity. Currently, there are no treatments which can regenerate brain tissue lost to infarction. Neural progenitor cells (NPCs) at the forefront of preclinical studies for regenerative stroke therapies. NPCs differentiate into replace neurons promote endogenous recovery mechanisms such as angiogenesis via trophic factor production release. The core is hypothetically ideal location replacement neural since it in situ develops a potential space where...
Abstract Glioblastoma multiforme (GBM) is an aggressive form of brain cancer that has no effective treatments and a prognosis only 12–15 months. Microfluidic technologies deliver microscale control fluids cells, have aided therapy as point‐of‐care devices for the diagnosis breast prostate cancers. However, few microfluidic are developed to study malignant glioma. The ability these platforms accurately replicate complex microenvironmental extracellular conditions prevailing in facilitate...
Particle ferrohydrodynamics and its device (FerroChip) enables label-free size-dependent separation of exosome-like nanoparticles with high recovery rate purity.
Glioblastoma multiforme (GBM) is the most aggressive form of astrocytoma accounting for a majority primary malignant brain tumors in United States. Chondroitin sulfate proteoglycans (CSPGs) and their glycosaminoglycan (GAG) side chains are key constituents extracellular matrix (ECM) implicated promoting tumor invasion. However, mechanisms by which sulfated CS-GAGs promote invasion currently unknown. We hypothesize that glioma cell triggered altered sulfation environment, this potentially...
Invasive spread of glioblastoma (GBM) is linked to changes in chondroitin sulfate (CS) proteoglycan (CSPG)‐associated sulfated glycosaminoglycans (GAGs) that are selectively up‐regulated the tumor microenvironment (TME). We hypothesized inhibiting CS‐GAG signaling TME would stem GBM invasion. Rat F98 cells demonstrated enhanced preferential cell invasion into oversulfated 3‐dimensional composite CSA and CS‐E [4‐ 4,6‐sulfated (COMP)] matrices compared with monosulfated (4‐sulfated) unsulfated...
Patients diagnosed with glioblastoma (GBM) receive a devastating prognosis of less than 15 months, and recurrence GBM is most often local, suggesting that regional therapies would serve both immediate long-term needs patients. Here, we investigate biomaterials-based approach for local delivery chimeric antigen receptor (CAR) T cells using murine model partial resection mimics patient recurrence. We demonstrate hydrogel CAR directly into the intracranial cavity can stably implant cellular...
Chimeric antigen receptor (CAR) T cells have demonstrated remarkable efficacy against hematological malignancies; however, they not experienced the same success solid tumors such as glioblastoma (GBM). There is a growing need for high-throughput functional screening platforms to measure CAR T-cell potency tumor cells.
Heparin and heparan sulfate (HS) are attractive components for constructing biomaterials due to their ability recruit regulate the activity of growth factors. The structural functional heterogeneity naturally derived heparin HS is, however, an impediment preparation regenerative medicine. To address this problem, we have prepared hydrogels modified by well-defined synthetic HS-derived disaccharides. Human induced pluripotent cell-derived neural stem cells (HIP-NSCs) encapsulated in a...
SUMMARY Patient-derived tumor organoids have been leveraged for disease modeling and preclinical studies, but rarely applied in real-time to aid with interpretation of patient treatment responses clinics. We recently demonstrated early efficacy signals a first-in-human, phase 1 study dual-targeting chimeric antigen receptor T cells (EGFR-IL13Rα2 CAR-T cells) patients recurrent glioblastoma. Here we analyzed six sets patient-derived glioblastoma (GBOs) treated concurrently the same autologous...
Abstract Treatment efficacy with chimeric antigen receptor (CAR) T cell therapy in glioblastoma (GBM) is undermined by an immunosuppressive tumor microenvironment (TME). We previously showed that CAR targeting epidermal growth factor variant III (EGFRvIII) produces anti-tumor activity against recurrent GBM and causes upregulation of programmed death-ligand 1 (PD-L1) the TME. Here, we conducted a phase I trial to study safety tolerability CART-EGFRvIII cells administered concomitantly PD-1...
Abstract Treatment efficacy with chimeric antigen receptor (CAR) T cell therapy in glioblastoma (GBM) is undermined by an immunosuppressive tumor microenvironment (TME). We previously showed that CAR targeting epidermal growth factor variant III (EGFRvIII) produces anti-tumor activity against recurrent GBM and causes upregulation of programmed death-ligand 1 (PD-L1) the TME. Here, we conducted a phase I trial to study impact CART-EGFRvIII cells administered concomitantly PD-1 inhibitor...
Abstract Glioblastoma (GBM) has shown remarkable resistance to peripherally administered CAR T cell therapy. This is in part because the nuanced requirements for successful CAR-T trafficking into brain tumors are not well understood. Intracranial administration been be both safe and effective delivery of other anti- cancer drugs GBM, with one example being Gliadel, involving placement carmustine chemotherapy-loaded wafers post-resection space sustained release local tissue. Recurrence GBM...
ABSTRACT Chimeric antigen receptor (CAR) T cells have shown significant efficacy in hematological diseases. However, CAR therapy has demonstrated limited solid tumors, including glioblastoma (GBM). One of the most important reasons is immunosuppressive tumor microenvironment (TME), which promotes growth and suppresses immune to eliminate cells. The human transforming factor-beta (TGF-β) plays a crucial role forming suppressive GBM TME driving suppression anti-GBM response. In order mitigate...
Abstract Patient-derived tumor organoids have been increasingly leveraged for disease modeling and preclinical studies, but rarely in real-time to aid with the interpretation of patient treatment responses clinical setting. Whether can be applied mirror activity patients even predict personalized medicine remains uncertain. We recently demonstrated promising early efficacy signals a first-in-human, phase 1 study dual-targeting chimeric antigen receptor T cells (EGFR-IL13Rα2 CAR-T cells)...